Updated on 2024/04/03

写真a

 
MITSUMA, Ayako
 
Organization
Nagoya University Hospital Clinical Oncology and Chemotherapy Lecturer of hospital
Title
Lecturer of hospital
Contact information
メールアドレス

Degree 1

  1. 医学博士 （ 2005.3   名古屋大学 ） 

To the head of Degree.▲

Research Interests 2

  1. がん薬物療法

  2. 医薬品副作用・薬物相互作用

To the head of Research Interests.▲

Research Areas 1

  1. Others / Others  / Applied Pharmacology

To the head of Research Areas.▲

Research History 1

  1. Nagoya University   Nagoya University Hospital Clinical Oncology and Chemotherapy

    2014.11

To the head of Research History.▲

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    1999.4 - 2003.3

    　 More details

    Country： Japan

  2. Nagoya University   Faculty of Medicine

    1988.4 - 1994.3

    　 More details

    Country： Japan

To the head of Education.▲

Professional Memberships 8

  1. 日本臨床腫瘍学会   理事、協議員（評議員）

    2011.7

  2. 日本臨床薬理学会   社員（評議員）

    2016.12

  3. 日本内科学会   会員、東海地方会評議員

  4. 日本血液学会   会員

  5. 日本癌治療学会   会員

  6. 日本癌学会   会員

  7. 日本緩和医療学会   会員

  8. 日本人類遺伝学会   会員

▼display all

To the head of Professional Memberships.▲

Awards 1

  1. 第43回日本臨床血液学会　学会奨励賞

    2002   日本臨床血液学会  

    　More details

    Country：Japan

To the head of Awards.▲
 

Papers 62

  1. Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer Reviewed

    Oguri Tomoyo, Mitsuma Ayako, Inada-Inoue Megumi, Morita Sachi, Shibata Takashi, Shimokata Tomoya, Sugishita Mihoko, Nakayama Goro, Uehara Keisuke, Hasegawa Yoshinori, Ando Yuichi

    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS   Vol. 51 ( 6 ) page： 475 - 481   2013.6

    　More details

    Authorship：Corresponding author   Publisher：International Journal of Clinical Pharmacology and Therapeutics  

    DOI： 10.5414/CP201851

    Web of Science

    Scopus

    PubMed

  2. Direct Observation of Retinal Microvessels in Cancer Patients After Systemic Administration of Bevacizumab and Oxaliplatin.

    Mitsuma A, Ito Y, Shimokata T, Tanaka C, Uehara K, Nakayama G, Terasaki H, Ando Y

    Cancer diagnosis & prognosis   Vol. 2 ( 3 ) page： 330 - 335   2022.5

    　More details

    Language：English  

    DOI： 10.21873/cdp.10113

    PubMed

  3. Overview of JSCN/JSMO/JASPO Joint Guidelines for Safe Handling of Cancer Chemotherapy Drugs in Japan Reviewed

    Kanda Kiyoko, Iino Keiko, Hirai Kazue, Kano Taro, Ichikawa Chisato, Iwamoto Sumiyo, Yasui Hisateru, Mitsuma Ayako, Nomura Hisanaga, Hiura Sumiko, Morita Tomoko, Komatsu Hiroko

    CANCER NURSING   Vol. 39   page： S108 - S109   2016

    　More details

  4. Transcriptional regulation of FKLF-2 (KLF13) gene in erythroid cells. Reviewed

    Mitsuma A, Asano H, Kinoshita T, Murate T, Saito H, Stamatoyannopoulos G, Naoe T

      Vol. 1727 ( 2 ) page： 125-133   2005

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  5. Extravasation of pegylated-liposomal doxorubicin: favorable outcome after immediate subcutaneous administration of corticosteroids. Reviewed

    Mitsuma A, Sawaki M, Shibata T, Morita S, Inada M, Shimokata T, Sugishita M, Kitagawa K, Sawada M, Nawa A , Ando Y

    Nagoya J. Med. Sci.   Vol. 74 ( 1-2 ) page： 189-192   2012

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  6. Cohort study exploring the effect of lenvatinib on differentiated thyroid cancer. Reviewed

    Tahara M, Takami H, Ito Y, Sugino K, Takahashi S, Takeyama H, Tsutsui H, Hara H, Mitsuma A, Yamashita H, Okamoto T, Sugitani I, Ohashi Y, Imai T

    Endocrine journal   Vol. 65 ( 11 ) page： 1071 - 1074   2018

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1507/endocrj.EJ18-0261

    Web of Science

    Scopus

    PubMed

  7. 特集 化学療法誘発性末梢神経障害(CIPN)　～しびれに悩む患者に,なにができるか～ Ⅰ.CIPNとは CIPNの機序

    満間 綾子

    がん看護   Vol. 28 ( 6 ) page： 533 - 536   2023.7

    　More details

    Publisher：南江堂  

    DOI： 10.15106/j_kango28_533

    CiNii Research

  8. Analysis of the COLLECT Study - Efficacy and safety of lenvatinib in differentiated thyroid cancer

    Iwasaki Hiroyuki, Takami Hiroshi, Yasuhiro Ito, Takahiro Okamoto, Iwao Sugitani, Kiminori Sugino, Shunji Takahashi, Hiroshi Takeyama, Hidemitsu Tutui, Hisato Hara, Ayako Mitsuma, Hiroyuki Yamashita, Yasuo Ohashi, Takeru Shiroiwa, Tuneo Imai, Makoto Tahara

    ANNALS OF ONCOLOGY   Vol. 33   page： S466 - S467   2022.7

    　More details

  9. A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

    Morita Sachi, Minami Hironobu, Mitsuma Ayako, Toyoda Masanori, Kiyota Naomi, Ando Yuichi

    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY     2022.1

    　More details

    Language：Japanese   Publisher：Asia-Pacific Journal of Clinical Oncology  

    Introduction: LCL161 is a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist. LCL161 enhances paclitaxel activity in cell lines and xenograft models. A phase I study of LCL161 combined with paclitaxel for the treatment of Japanese patients with advanced solid tumors was conducted. Methods: Each patient received oral LCL161 in a single weekly dose on days 1, 8, and 15 of a 21-day treatment cycle. In the second cycle, patients received a combination treatment with weekly paclitaxel (80 mg/m2) whenever possible. A Bayesian logistic regression model by escalation with the overdose control principle was used. Results: Nine patients were treated with LCL161 at a dose of 600 mg (five patients) or 1200 mg (four patients). Seven patients were treated with LCL161 plus paclitaxel, and two patients received only LCL161 monotherapy. Because this study was terminated early due to a change in the LCL161 development strategy, the maximum tolerated dose (MTD) was not determined. One patient treated with LCL161 monotherapy at a dose of 1200 mg experienced dose limitind toxicity (grade 3 maculopapular rash). Another patient died on day 86 of bacterial pneumonia, which was suspected to be related to the study treatment. The most common serious adverse events were infections and infestations (n = 3). Conclusion: The present study suggests that the risk of infection may increase when LCL161 is combined with paclitaxel, but other conclusions about the MTD, pharmacokinetic profile, and preliminary activity of the combination of LCL161 plus paclitaxel were not drawn.

    DOI： 10.1111/ajco.13744

    Web of Science

    Scopus

    PubMed

  10. Chemotherapy for Older Patients with Cancer

    Mitsuma A., Ando Y.

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 49 ( 1 ) page： 13 - 18   2022.1

    　More details

    Publisher：Gan to kagaku ryoho. Cancer & chemotherapy  

    Older patients with cancer are different physically, psycho-spirituality, and socio-economically, and when considering the indications for chemotherapy and other drug therapies for cancer, it is important to comprehensively assess their condition and risk using geriatric assessment(GA). Multidisciplinary team-based approach is essential to address impaired domains that are found by GA. The G8 screening is useful tool for screening the GA candidates. In recent years, there have been increasing opportunities that older patients with cancer who receive immunotherapy with immune checkpoint inhibitors. There is no consensus on the treatment and management of immune-related adverse events(irAEs)specific to older patients, and therefore it is important to adhere to an evidence-based approach.

    Scopus

  11. Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

    Takano Yuko, Furune Satoshi, Miyai Yuki, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page： 67 - 70   2022.1

    　More details

  12. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page： 46 - 48   2022.1

    　More details

  13. [Chemotherapy for Older Patients with Cancer].

    Mitsuma A, Ando Y

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 49 ( 1 ) page： 13 - 18   2022.1

    　More details

    Language：Japanese  

    PubMed

  14. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page： 49 - 49   2022.1

    　More details

  15. A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

    Takano Yuko, Furune Satoshi, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Osamu Maeda, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 32   page： S354 - S354   2021.7

    　More details

  16. Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer.

    Tahara Makoto, Takami Hiroshi, Ito Yasuhiro, Okamoto Takahiro, Sugitani Iwao, Sugino Kiminori, Takahashi Shunji, Takeyama Hiroshi, Tsutsui Hidemitsu, Hara Hisato, Mitsuma Ayako, Yamashita Hiroyuki, Ohashi Yasuo, Imai Tsuneo

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 39 ( 15 )   2021.5

    　More details

  17. Collision Tumors of Gastric Adenocarcinoma and Mucosa-associated Lymphoid Tissue Lymphoma

    Kobayashi Kenichi, Furukawa Kazuhiro, Ishikawa Eri, Mitsuma Ayako, Funasaka Kohei, Kakushima Naomi, Furune Satoshi, Ito Nobuhito, Wada Hirotaka, Hirose Takashi, Muroi Koichi, Suzuki Tomohiko, Suzuki Takahiro, Hida Emiko, Hirai Keiko, Shibata Hiroyuki, Koya Toshinari, Nakamura Masanao, Kawashima Hiroki, Miyahara Ryoji, Fujishiro Mitsuhiro

    INTERNAL MEDICINE   Vol. 60 ( 15 ) page： 2419 - 2424   2021

    　More details

    Language：Japanese   Publisher：一般社団法人 日本内科学会  

    <p>A 65-year-old woman with a history of treatment for splenic marginal zone B-cell lymphoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma underwent esophagogastroduodenoscopy. A reddish elevated lesion was found in the fundus of the stomach. On image-enhanced endoscopy, several findings, such as glandular structures of varying sizes suggesting well-differentiated adenocarcinoma, pruned blood vessels, and dilated blood vessels in deeper mucosa suggesting MALT lymphoma, were observed. The final pathological diagnosis after surgical resection was collision tumors of well-differentiated adenocarcinoma and MALT lymphoma. The features of both tumors could be observed simultaneously with image-enhanced endoscopy. </p>

    DOI： 10.2169/internalmedicine.6124-20

    Web of Science

    Scopus

    PubMed

  18. 抗がん薬曝露対策のTip and Trick―Beyond the Guideline 「メディカルサーベイランス」

    満間 綾子

    月刊薬事   Vol. vol.61 No.5   page： 74 - 78   2019

    　More details

  19. 3.抗がん薬の臨床薬理学～分子標的薬とその心毒性～

    満間 綾子, 安藤 雄一

    医薬ジャーナル   Vol. vol.54 No.12   2018

    　More details

  20. Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device

    Matsuoka, A; Mitsuma, A; Maeda, O; Kajiyama, H; Kiyoi, H; Kodera, Y; Nagino, M; Goto, H; Ando, Y

    CANCER SCIENCE   Vol. 107 ( 10 ) page： 1453 - 1457   2016.10

    　More details

    Language：English   Publisher：Wiley  

    <jats:p>Chemotherapy‐induced peripheral neurotoxicity (<jats:styled-content style="fixed-case">CIPN</jats:styled-content>) seriously impairs patients’ quality of life cumulatively and dose‐dependently. Because assessment of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> usually depends on patients’ subjective evaluation of symptoms, objective and quantitative measures are needed. We evaluated a point‐of‐care nerve conduction device (<jats:styled-content style="fixed-case">POCD</jats:styled-content>), previously validated for the assessment of diabetic peripheral neuropathy. Sensory nerve action potential (<jats:styled-content style="fixed-case">SNAP</jats:styled-content>) amplitude and sensory nerve conduction velocity (<jats:styled-content style="fixed-case">SNCV</jats:styled-content>) of the sural nerve were measured using a portable, automated <jats:styled-content style="fixed-case">POCD</jats:styled-content> (DPNCheck; NeuroMetrix Inc., Waltham, MA, USA) in patients with a clinical diagnosis of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> of grade 1 or higher. We compared <jats:styled-content style="fixed-case">SNAP</jats:styled-content> and <jats:styled-content style="fixed-case">SNCV</jats:styled-content> among patients with different grades of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> according to the Common Terminology Criteria for Adverse Events. A total of 50 patients (22 men, 28 women; median age, 64 years; grade 1/2/3, 21/18/11) were evaluated. Anticancer drugs responsible for <jats:styled-content style="fixed-case">CIPN</jats:styled-content> were cisplatin in five patients, oxaliplatin in 15, carboplatin in 5, paclitaxel in 16, docetaxel in 14, nab‐paclitaxel in 7, vincristine in 6, and bortezomib in 3. Unadjusted <jats:styled-content style="fixed-case">SNAP</jats:styled-content> was 8.45 ± 3.67 μV (mean ± SD) in patients with grade 1 <jats:styled-content style="fixed-case">CIPN</jats:styled-content>, 5.42 ± 2.68 μV with grade 2, and 2.45 ± 1.52 μV with grade 3. Unadjusted <jats:styled-content style="fixed-case">SNCV</jats:styled-content> was 49.71 ± 4.77 m/s in patients with grade 1 <jats:styled-content style="fixed-case">CIPN</jats:styled-content>, 48.78 ± 6.33 m/s with grade 2, and 44.14 ± 7.31 m/s with grade 3. The adjusted <jats:styled-content style="fixed-case">SNAP</jats:styled-content> after controlling for age significantly differed between each <jats:styled-content style="fixed-case">CTCAE</jats:styled-content> grade (<jats:italic>P</jats:italic> < 0.001, <jats:sc>ancova</jats:sc>). The adjusted <jats:styled-content style="fixed-case">SNCV</jats:styled-content> after controlling for age and height also differed significantly (<jats:italic>P</jats:italic> = 0.027). Differences in the severity of <jats:styled-content style="fixed-case">CIPN</jats:styled-content> could be detected objectively and quantitatively using this <jats:styled-content style="fixed-case">POCD</jats:styled-content>.</jats:p>

    DOI： 10.1111/cas.13010

    Web of Science

    Scopus

    PubMed

    CiNii Research

  21. 特集:癌化学療法に伴う神経障害性疼痛-最近の研究動向 臨床現場からの情報発信:「オキサリプラチンによる末梢神経障害の遺伝的背景」

    満間 綾子, 安藤 雄一

    日本薬理学会誌   Vol. vol.141 No.2   page： 62 - 65   2013

    　More details

  22. 特集PK-PDとPGxの最前線 「がん分子標的薬のPK-PDとPGx」

    満間 綾子, 安藤 雄一

    月刊薬事   Vol. vol.52 No.4   page： 39 - 46   2010

    　More details

  23. Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

    Minami Hironobu, Doi Toshihiko, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Mitsuma Ayako, Shimokata Tomoya, Naito Yoichi, Matsubara Nobuaki, Tajima Takeshi, Tokushige Kota, Ishihara Kae, Cameron Scott, Ando Yuichi

    CANCER SCIENCE   Vol. 112 ( 2 ) page： 725 - 733   2021.2

    　More details

    Publisher：Cancer Science  

    DOI： 10.1111/cas.14678

    Web of Science

    Scopus

    PubMed

  24. Chemotherapy for biliary tract cancer: real-world experience in a single institute

    Maeda Osamu, Ebata Tomoki, Shimokata Tomoya, Matsuoka Ayumu, Inada-Inoue Megumi, Morita Sachi, Takano Yuko, Urakawa Hiroshi, Miyai Yuki, Sugishita Mihoko, Mitsuma Ayako, Ando Masahiko, Mizuno Takashi, Nagino Masato, Ando Yuichi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page： 725 - 733   2020.11

    　More details

    Publisher：Nagoya Journal of Medical Science  

    DOI： 10.18999/nagjms.82.4.725

    Web of Science

    Scopus

    PubMed

  25. Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

    Maeda Osamu, Ohka Fumiharu, Maesawa Satoshi, Matsuoka Ayumu, Shimokata Tomoya, Mitsuma Ayako, Urakawa Hiroshi, Nakamura Shota, Shimoyamas Yoshic, Nakaguro Masato S., Wakabayashi Toshihiko, Ando Yuichi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page： 631 - 644   2020.11

    　More details

    Publisher：Nagoya Journal of Medical Science  

    DOI： 10.18999/nagjms.82.4.631

    Web of Science

    Scopus

    PubMed

  26. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

    Urakawa Hiroshi, Ando Yuichi, Hase Tetsunari, Kikumori Toyone, Arai Eisuke, Maeda Osamu, Mitsuma Ayako, Sugishita Mihoko, Shimokata Tomoya, Ikuta Kunihiro, Ishiguro Naoki, Nishida Yoshihiro

    INTERNATIONAL JOURNAL OF CANCER   Vol. 146 ( 12 ) page： 3504 - 3515   2020.6

    　More details

    Publisher：International Journal of Cancer  

    DOI： 10.1002/ijc.32836

    Web of Science

    Scopus

    PubMed

  27. Detection of bacteria in blood circulation in patients receiving cancer chemotherapy.

    Ota A, Morita S, Matsuoka A, Shimokata T, Maeda O, Mitsuma A, Yagi T, Asahara T, Ando Y

    International journal of clinical oncology   Vol. 25 ( 1 ) page： 210 - 215   2020.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s10147-019-01521-y

    Web of Science

    Scopus

    PubMed

  28. A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity

    Matsuoka A., Mitsuma A., Maeda O., Tsunoda N., Kikumori T., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 30   2019.10

    　More details

  29. Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies

    Ando Yuichi, Doi Toshihiko, Mitsuma Ayako, Mizutani Takefumi, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Naito Yoichi, Matsubara Nobuaki, Ishihara Kae, Tajima Takeshi, Tokushige Kota, Cameron Scott, Minami Hironobu

    ANNALS OF ONCOLOGY   Vol. 29   page： .   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

  30. Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas

    Urakawa Hiroshi, Nishida Yoshihiro, Mitsuma Ayako, Maeda Osamu, Sugishita Mihoko, Shimokata Tomoya, Mizutani Takeshi, Arai Eisuke, Ikuta Kunihiro, Hamada Shunsuke, Ota Takehiro, Ishiguro Naoki, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 29   page： .   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

  31. A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity

    Matsuoka A., Maeda O., Mitsuma A., Uehara K., Nakayama G., Nagino M., Kodera Y., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 29   page： .   2018.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

  32. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)

    Nakayama Goro, Mitsuma Ayako, Sunagawa Yuki, Ishigure Kiyoshi, Yokoyama Hiroyuki, Matsui Takanori, Nakayama Hiroshi, Nakata Kazuhiko, Ishiyama Akiharu, Asada Takahiro, Umeda Shinichi, Ezaka Kazuhiro, Hattori Norifumi, Takami Hideki, Kobayashi Daisuke, Tanaka Chie, Kanda Mitsuro, Yamada Suguru, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro

    ONCOLOGIST   Vol. 23 ( 8 ) page： 919 - 927   2018.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1634/theoncologist.2017-0640

    Web of Science

    Scopus

    PubMed

  33. Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

    Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28   page： 69-69   2017.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Web of Science

  34. Erratum: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.

    Yamamoto E, Niimi K, Fujikake K, Nishida T, Murata M, Mitsuma A, Ando Y, Kikkawa F

    Molecular and clinical oncology   Vol. 7 ( 3 ) page： 510   2017.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.3892/mco.2017.1315

    PubMed

  35. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer

    Honda Kazunori, Takeshita Kyosuke, Murotani Kenta, Mitsuma Ayako, Hayashi Hironori, Tsunoda Nobuyuki, Kikumori Toyone, Murohara Toyoaki, Ando Yuichi

    BREAST CANCER   Vol. 24 ( 2 ) page： 312 - 318   2017.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1007/s12282-016-0705-4

    Web of Science

    Scopus

    PubMed

  36. Salient features and outline of the joint Japanese guidelines for safe handling of cancer chemotherapy drugs

    Kanda Kiyoko, Hirai Kazue, Iino Keiko, Nomura Hisanaga, Yasui Hisateru, Kano Taro, Ichikawa Chisato, Hiura Sumiko, Morita Tomoko, Mitsuma Ayako, Komatsu Hiroko

    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING   Vol. 4 ( 4 ) page： 304 - 312   2017

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.4103/apjon.apjon_30_17

    Web of Science

    PubMed

  37. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review

    Yamamoto Eiko, Niimi Kaoru, Fujikake Kayo, Nishida Tetsuya, Murata Makoto, Mitsuma Ayako, Ando Yuichi, Kikkawa Fumitaka

    MOLECULAR AND CLINICAL ONCOLOGY   Vol. 5 ( 5 ) page： 660 - 664   2016.11

    　More details

    Publisher：Molecular and Clinical Oncology  

    DOI： 10.3892/mco.2016.1011

    Web of Science

    Scopus

    PubMed

  38. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer

    Sugishita Mihoko, Imai Tsuneo, Kikumori Toyone, Mitsuma Ayako, Shimokata Tomoya, Shibata Takashi, Morita Sachi, Inada-Inoue Megumi, Sawaki Masataka, Hasegawa Yoshinori, Ando Yuichi

    BREAST CANCER   Vol. 23 ( 2 ) page： 195 - 201   2016.3

    　More details

  39. Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction

    Shibata Takashi, Ebata Tomoki, Fujita Ken-ichi, Shimokata Tomoya, Maeda Osamu, Mitsuma Ayako, Sasaki Yasutsuna, Nagino Masato, Ando Yuichi

    CANCER SCIENCE   Vol. 107 ( 2 ) page： 168 - 172   2016.2

    　More details

    Publisher：Cancer Science  

    DOI： 10.1111/cas.12851

    Web of Science

    Scopus

    PubMed

  40. Development of "Guidelines for Safe Handling of Cancer Chemotherapy Drugs" in Japan

    Hirai Kazue, Kanda Kiyoko, Iino Keiko, Kano Taro, Ichikawa Chisato, Iwamoto Sumiyo, Yasui Hisateru, Mitsuma Ayako, Nomura Hisanaga, Hiura Sumiko, Morita Tomoko, Komatsu Hiroko

    CANCER NURSING   Vol. 39   page： S89 - S90   2016

    　More details

  41. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer

    Mukai Hirofumi, Masuda Norikazu, Ishiguro Hiroshi, Mitsuma Ayako, Shibata Takashi, Yamamura Jun, Toi Masakazu, Watabe Aiko, Sarashina Akiko, Uttenreuther-Fischer Martina, Ando Yuichi

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 76 ( 4 ) page： 739 - 750   2015.10

    　More details

    Publisher：Cancer Chemotherapy and Pharmacology  

    DOI： 10.1007/s00280-015-2826-4

    Web of Science

    Scopus

    PubMed

  42. Pazopanib monotherapy in a patient with a malignant granular cell tumor originating from the right orbit: A case report

    Morita Sachi, Hiramatsu Mariko, Sugishita Mihoko, Gyawali Bishal, Shibata Takashi, Shimokata Tomoya, Urakawa Hiroshi, Mitsuma Ayako, Moritani Suzuko, Kubota Toshinobu, Ichihara Shu, Ando Yuichi

    ONCOLOGY LETTERS   Vol. 10 ( 2 ) page： 972 - 974   2015.8

    　More details

    Publisher：Oncology Letters  

    DOI： 10.3892/ol.2015.3263

    Web of Science

    Scopus

    PubMed

  43. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer

    Yoshioka Yuichiro, Uehara Keisuke, Ebata Tomoki, Yokoyama Yukihiro, Mitsuma Ayako, Ando Yuichi, Nagino Masato

    SURGERY TODAY   Vol. 44 ( 7 ) page： 1300 - 1306   2014.7

    　More details

  44. Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia

    Shibata Takashi, Minami Yosuke, Mitsuma Ayako, Morita Sachi, Inada-Inoue Megumi, Oguri Tomoyo, Shimokata Tomoya, Sugishita Mihoko, Naoe Tomoki, Ando Yuichi

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   Vol. 19 ( 2 ) page： 391 - 396   2014.4

    　More details

    Publisher：International Journal of Clinical Oncology  

    DOI： 10.1007/s10147-013-0562-5

    Web of Science

    Scopus

    PubMed

  45. Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors

    Inada-Inoue Megumi, Ando Yuichi, Kawada Kenji, Mitsuma Ayako, Sawaki Masataka, Yokoyama Taro, Sunakawa Yu, Ishida Hiroo, Araki Kazuhiro, Yamashita Keishi, Mizuno Keiko, Nagashima Fumio, Takekura Akiko, Nagamatsu Kazuo, Sasaki Yasutsuna

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 73 ( 4 ) page： 673 - 683   2014.4

    　More details

    Publisher：Cancer Chemotherapy and Pharmacology  

    DOI： 10.1007/s00280-014-2374-3

    Web of Science

    Scopus

    PubMed

  46. Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors

    Ando Yuichi, Inada-Inoue Megumi, Mitsuma Ayako, Yoshino Takayuki, Ohtsu Atsushi, Suenaga Naoko, Sato Masahiko, Kakizume Tomoyuki, Robson Matthew, Quadt Cornelia, Doi Toshihiko

    CANCER SCIENCE   Vol. 105 ( 3 ) page： 347 - 353   2014.3

    　More details

    Publisher：Cancer Science  

    DOI： 10.1111/cas.12350

    Web of Science

    Scopus

    PubMed

  47. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors including breast cancer

    Masuda N., Mukai H., Ishiguro H., Mitsuma A., Shibata T., Yamamura J., Toi M., Watabe A., Sarashina A., Ebisawa R., Uttenreuther-Fischer M., Ando Y.

    CANCER RESEARCH   Vol. 73   2013.12

    　More details

  48. A Phase l study of BYL719, an alpha-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies.

    Kogure Yoshihito, Yamada Yasuhide, Saka Hideo, Kitagawa Chiyoe, Iwasa Satoru, Yamamoto Noboru, Aoki Takuji, Kakizume Tomoyuki, Robson Matthew, Quadt Cornelia, Mitsuma Ayako, Shibata Takashi, Ando Yuichi

    MOLECULAR CANCER THERAPEUTICS   Vol. 12 ( 11 )   2013.11

    　More details

  49. A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors

    Fujiwara Yutaka, Ando Yuichi, Mukohara Toru, Kiyota Naomi, Chayahara Naoko, Mitsuma Ayako, Inada-Inoue Megumi, Sawaki Masataka, Ilaria Robert Jr., Turner P. Kellie, Funai Jumpei, Maeda Kaijiro, Minami Hironobu

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 71 ( 4 ) page： 991 - 998   2013.4

    　More details

    Publisher：Cancer Chemotherapy and Pharmacology  

    DOI： 10.1007/s00280-013-2092-2

    Web of Science

    Scopus

    PubMed

  50. Genetic backgrounds of peripheral neuropathy induced by oxaliplatin

    MITSUMA Ayako, ANDO Yuichi

    Folia Pharmacologica Japonica   Vol. 141 ( 2 ) page： 62 - 5   2013.2

    　More details

    Publisher：The Japanese Pharmacological Society  

    DOI： 10.1254/fpj.141.62

    PubMed

  51. Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer

    Morita Sachi, Uehara Keisuke, Nakayama Goro, Shibata Takashi, Oguri Tomoyo, Inada-Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Ando Yuichi

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 71 ( 2 ) page： 405 - 411   2013.2

    　More details

    Publisher：Cancer Chemotherapy and Pharmacology  

    DOI： 10.1007/s00280-012-2028-2

    Web of Science

    Scopus

    PubMed

  52. Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

    Morita Sachi, Oizumi Satoshi, Minami Hironobu, Kitagawa Koichi, Komatsu Yoshito, Fujiwara Yutaka, Inada Megumi, Yuki Satoshi, Kiyota Naomi, Mitsuma Ayako, Sawaki Masataka, Tanii Hiromi, Kimura Junko, Ando Yuichi

    INVESTIGATIONAL NEW DRUGS   Vol. 30 ( 5 ) page： 1950 - 1957   2012.10

    　More details

    Publisher：Investigational New Drugs  

    DOI： 10.1007/s10637-011-9751-0

    Web of Science

    Scopus

    PubMed

  53. Peripheral neuropathy induced by oxaliplatin is associated with genetic polymorphisms

    Mitsuma A., Oguri T., Inada M., Ando Y.

    JOURNAL OF NEUROLOGY   Vol. 259   page： S126 - S126   2012.6

    　More details

  54. Pharmacokinetic Study of S-1 in Patients in Whom Inulin Clearance Was Measured

    Ando Yuichi, Kawada Kenji, Inada Megumi, Morita Sachi, Mitsuma Ayako, Yasuda Yoshinari, Hiramatsu Mariko, Fujimoto Yasushi, Fujita Ken-ichi

    ONCOLOGY   Vol. 83 ( 1 ) page： 38 - 44   2012

    　More details

    Publisher：Oncology (Switzerland)  

    DOI： 10.1159/000337232

    Web of Science

    Scopus

    PubMed

  55. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.

    Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, Sawaki M, Fujita K, Ando Y

    International journal of clinical pharmacology and therapeutics   Vol. 48 ( 11 ) page： 729 - 34   2010.11

    　More details

    Publisher：International Journal of Clinical Pharmacology and Therapeutics  

    DOI： 10.5414/cpp48729

    Scopus

    PubMed

  56. The Feasibility Study of Docetaxel in Patients with Anaplastic Thyroid Cancer

    Kawada Kenji, Kitagawa Koichi, Kamei Sachi, Nada Megumi, Mitsuma Ayako, Sawaki Masataka, Kikumori Toyone, Fujimoto Yasushi, Arima Hiroshi, Imai Tsuneo, Ando Yuichi

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   Vol. 40 ( 6 ) page： 596 - 599   2010.6

    　More details

    Publisher：Japanese Journal of Clinical Oncology  

    DOI： 10.1093/jjco/hyq025

    Web of Science

    Scopus

    PubMed

  57. 5. Standard Chemotherapy of Hematological Cancers

    Mitsuma Ayako, Naoe Tomoki

    Nihon Naika Gakkai Zasshi   Vol. 98 ( 8 ) page： 1880 - 6   2009.8

    　More details

    Publisher：The Japanese Society of Internal Medicine  

    DOI： 10.2169/naika.98.1880

    PubMed

  58. Transcriptional regulation of FKLF-2 (KLF13) gene in erythroid cells

    Mitsuma A, Asano H, Kinoshita T, Murate T, Saito H, Stamatoyannopoulos G, Naoe T

    BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION   Vol. 1727 ( 2 ) page： 125 - 133   2005.2

    　More details

    Publisher：Biochimica et Biophysica Acta - Gene Structure and Expression  

    DOI： 10.1016/j.bbaexp.2004.12.007

    Web of Science

    Scopus

    PubMed

  59. Functional importance of FKLF-2 in erythroid cell development

    MITSUMA Ayako

    Rinsho Ketsueki   Vol. 44 ( 2 ) page： 70 - 75   2003.2

    　More details

    Publisher：The Japanese Society of Hematology  

    DOI： 10.11406/rinketsu.44.70

  60. [Functional importance of FKLF-2 in erythroid cell development].

    Mitsuma A

    [Rinsho ketsueki] The Japanese journal of clinical hematology   Vol. 44 ( 2 ) page： 70 - 5   2003.2

    　More details

  61. Transcriptional regulation of FKLF-2 expressed in erythroid cells.

    Mitsuma A, Asano H, Stamatoyannopoulos G, Kinoshita T, Murate T, Saito H

    BLOOD   Vol. 98 ( 11 ) page： 129B - 129B   2001.11

    　More details

  62. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.

    Hirabayashi N, Goto S, Ishii M, Yuge M, Mitsuma A, Noda N

    Bone marrow transplantation   Vol. 21 ( 11 ) page： 1079 - 83   1998.6

    　More details

▼display all

To the head of Papers.▲

Books 2

  1. 「化学療法誘発性末梢神経障害（CIPN）の機序」　

    満間綾子（ Role： Contributor）

    南江堂  2023 

    　More details

    Responsible for pages：p533-536   Language：Japanese Book type：Scholarly book

    「がん看護」2023年7/8月号《総 説》化学療法誘発性末梢神経障害（CIPN）～しびれに悩む患者に、なにができるか～

  2. 「がん薬物療法」

    満間綾子、安藤雄一（ Role： Joint author）

    羊土社  2023 

    　More details

    Responsible for pages：p1231-1236   Language：Japanese Book type：Textbook, survey, introduction

    レジデントノート増刊　今こそ学び直す！薬理学

To the head of Books.▲

Presentations 2

  1. 高齢がん患者における外来化学療法の現状

    満間 綾子、岡田 咲樂、栁川まどか、池田 義明、安藤 雄一

    第34回　日本老年医学会　東海地方会  2023.10.21  日本老年医学会

    　More details

    Event date： 2023.10

    Language：Japanese   Presentation type：Poster presentation  

    Venue：名古屋  

  2. 外来化学療法中の高齢がん患者におけるベンゾジアゼピン系薬剤(BEZ)処方と転倒リスクの検討

    岡田 咲樂、満間 綾子、宮崎雅之、池田 義明、安藤 雄一

    第33回 日本医療薬学会学術集会 

To the head of Presentations.▲

KAKENHI (Grants-in-Aid for Scientific Research) 10

  1. がん薬物療法における抗がん薬曝露に対する科学的エビデンスの創出

    Grant number：19K07083  2019.4 - 2024.3

    満間 綾子

    　 More details

    Authorship：Principal investigator 

    Grant amount：\3120000 （ Direct Cost: \2400000 、 Indirect Cost：\720000 ）

    新規抗がん薬の開発により、外来化学療法で取り扱う抗がん薬レジメンは増加する一方である。外来化学療法室の利用患者は年々増加し、多様なニーズに応えるがん薬物療法に習熟した医療者の関わりが重要となっている。がん薬物療法を専門とする医療者の育成、拡充にあたっては、専門的な教育・訓練とともに抗がん薬を扱う現場における医療者の安全、職場環境の整備も提唱されている。曝露防止のための機器開発が進む中で過去の報告は現状と乖離しており、医療者がコストと時間をかけてどこまで曝露対策を行うかの科学的実証は未確立である。本研究では、抗がん薬曝露の実態を経年的・経時的に調査し現状に即したエビデンスを創出する。
    本研究では、がん薬物療法における抗がん薬曝露の実態を調査し、繰り返しモニタリングを行うことで、国内での閾値の設定や予防の根拠となるエビデンスを創出することを目的としている。当院外来化学療法室では、院内すべての点滴抗がん薬の外来投与を専任の医療者が担当している。年間10000件以上の実施にあたり、職業性曝露のモニタリングとして環境モニタリングと生物学的モニタリングの経年的実施を行う。
    ＜環境モニタリング＞
    当院外来化学療法室での環境モニタリングを行うにあたり、モニタリングの手法、場所を絞り込んだ後に、抗がん薬曝露予防を目的とした機器導入、マニュアルの改訂・整備の現状を把握できている。閉鎖式薬物移送システム(closed system drug transfer device: CSTD) は、当院において抗がん薬のミキシングすべてには使用していない。揮発性抗がん薬であるベンダムスチン、イホスファミド、シクロホスファミドにはCSTDを使用しているのが実情であり、現状でのモニタリングを進めている。
    ＜生物学的モニタリング＞
    外来化学療法室で実施する膀胱内注入後の抗がん薬曝露について、同意を得た患者および医療者の排尿より生物学的モニタリングを行う。ドキソルビシンの投与が予定されており、投与量、排尿回数など臨床薬理学的解析を加えて経時的変化を観察する予定であったが、治療対象者が乏しい状況が続いている。がん関連学会での情報収集を継続し、侵襲の程度が少ない新たな手法（唾液検体からの検出）について検討中である。
    環境モニタリングは順調に推移している。生物学的モニタリングは対象患者が乏しい状況があった。
    生物学的モニタリングの対象となる泌尿器疾患の患者が前年度と比較し減少あり、このまま減少していれば、協力可能な新たな対象者を検討する。がん薬物療法の分野では新たな治療法の開発により治療選択が変遷する場合もあり、状況に応じて研究代表者および研究分担者とも討議し研究の推進に努める。
    また、生物学的モニタリングの検体として排尿時の尿検体を対象としていたが、新たに唾液採取からの検出手法が開発されており、侵襲が少なく簡便な手段として検討する。

  2. Screening and prevention of vascular events for cancer patients, and investigation of the mechanisms.

    Grant number：16K08906  2016.4 - 2020.3

    Mitsuma Ayako

    　 More details

    Authorship：Principal investigator 

    Grant amount：\2730000 （ Direct Cost: \2100000 、 Indirect Cost：\630000 ）

    Some newly developed cancer chemotherapy drugs cause hemorrhage or thrombosis as adverse event through inhibition of angiogenesis. Prolonged survival and aging of cancer patients lead to increase of patients using anticoagulats to prevent cardiovascular disease. In this study we evaluated risk of cancer associated thrombosis receiving outpatient treatment, including drug interactions. We compared our data with predictive model proposed in foreign studies. We found no difference in outcome of treatment with specific anticoagulants. Effects of cancer chemotherapy and condition of patients influenced clinical course of thrombosis.

  3. Genetic backgrounds of peripheral neuropathy induced by chemotherapy

    Grant number：22590500  2010 - 2012

    Grant-in-Aid for Scientific Research 

    MITSUMA Ayako

    　 More details

    Authorship：Principal investigator 

    Grant amount：\2080000 （ Direct Cost: \1600000 、 Indirect Cost：\480000 ）

    Severe adverse effect often makes it impossible to continue anticancer chemotherapy. Oxaliplatin is one of the key drugs for adjuvant and palliative chemotherapy in colorectal cancer patients. Development of Oxaliplatin-induced peripheral neuropathy is cumulative and dose-limiting. Analysis of Japanese colorectal cancer patients revealed correlation between polymorphisms related to metabolism of Oxaliplatin and onset of neuropathies. This result is useful for identifying predictors of Oxaliplatin-induced neuropathy and may be useful for personalized chemotherapy. Ethical differences were also found compared to previous studies.

  4. Exploring biomarkers for immune checkpoint inhibitors in elderly patients with cancer

    Grant number：22K07415  2022.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    　 More details

    Authorship：Coinvestigator(s) 

  5. Mechanism of diarrhea/enteritis caused by anticancer drugs and development of new treatment

    Grant number：17K08950  2017.4 - 2020.3

    Ando Yuichi

    　 More details

    Authorship：Coinvestigator(s) 

    By focusing on bacterial-translocation, phenomenon in which human intestinal bacteria migrate into circulating blood in human body via intestinal wall, using highly-sensitive detection assay for viable bacteria, I investigated whether bacteria in the blood would be associated with the occurrence of adverse effects of cancer chemotherapy. The results revealed that patients with cancer were always prone to bacterial-translocations regardless of the administration of anticancer drugs, suggesting that bacterial-translocation would be the cause of febrile neutropenia, infection, and diarrhea/enteritis, which are caused by cancer chemotherapy.

  6. Elucidation of sarcopenia mechanism in the cancer cachexia

    Grant number：15K08906  2015.4 - 2019.3

    Shimokata Tomoya

    　 More details

    Authorship：Coinvestigator(s) 

    We evaluated the body composition, muscle mass and adipose tissue, in patients who received cancer pharmacotherapy to test a hypothesis that the adipose tissue plays an important role in the process to cancer cachexia. We analyzed the change of the body composition in patients who received monotherapy of the mTOR inhibitor more than six months retrospectively. The muscle mass significantly decreased, but there were no significant changes in the adipose tissue quantity. Also, we performed a cohort study to evaluate a body composition change and a metabolic rate as subjects in the patients prospectively. We accumulate 28 cases and final analysis is in progress.

  7. Clinical significance of sarcopenia in cancer chemotherapy

    Grant number：26460626  2014.4 - 2018.3

    Ando Yuichi

    　 More details

    Authorship：Coinvestigator(s) 

    The aim of this study is investigated sarcopenia in cancer patients who underwent cancer chemotherapy in order to test the hypothesis that those patients with sarcopenia are more likely to experience severe toxicity and then poorly tolerate the treatment. First, we retrospectively analyzed the change of skeletal muscle mass in patients treated with an mTOR inhibitor and reported that the muscle mass was significantly reduced by treatment. Subsequently, an observational study was conducted to prospectively evaluate sarcopenia up to for 6 months in cancer patients who received a kinase inhibitor containing mTOR inhibitor. Of the 28 patients enrolled, 17 and 7 patients completed the 6-month and 3-month follow-ups, respectively. Final analysis of the results is in progress.

  8. Ophthalmologic assessment of retinal vessels as a biomarker of the pharmacological response to antiangiogenic cancer chemotherapy

    Grant number：23590638  2011 - 2013

    ANDO YUICHI

    　 More details

    Authorship：Coinvestigator(s) 

    To explore biomarkers of the pharmacological response to cancer chemotherapy including angiogenic inhibitors, this research assessed ophthalmologic findings of retinal vessels of total 137 patients who receiving cancer chemotherapy. The retinal vessel diameters; were more likely to shrink in those who responded to the preoperative treatment of colorectal cancer; clearly reflected therapeutic efficacy in those with refractory multiple myeloma; and showed a marked reduction in those who obtained long-term stable disease during the treatment of metastatic colorectal cancer.

  9. Clinical and genetic factors of drug-induced QT interval prolongation in patients who receive cancer chemotherapy

    Grant number：20590537  2008 - 2010

    ANDO Yuichi

    　 More details

    Authorship：Coinvestigator(s) 

    This study assessed the characteristics of QT intervals and arrhythmias in women with breast cancer who received chemotherapy with a combination of epirubicin, cyclophosphamide and 5-fluorouracil. QT intervals could be measured in 127 records in 34 patients. There was a significant trend toward QT interval prolongation after each treatment. No patient had serious arrhythmias. There was no association between QT interval prolongation and the SNPs of potassium channel genes.

  10. Identification of Epithelial-to-Mesenchymal Transition-Associated Genes as Therapeutic Targets for Lung Cancer

    Grant number：20590919  2008 - 2010

    SATO Mitsuo

    　 More details

    Authorship：Coinvestigator(s) 

    The aim of this study is to identify epithelial-to-mesenchymal transition (EMT)-associated genes as novel therapeutic targets for lung cancer. While several EMT-inducing genes have been discovered, which of these have the dominant role in EMT of lung cancer was not clear. We found that among four EMT-inducing genes (ZEB1, TWIST, SLUG, SIP1) ZEB1 plays the dominant role in EMT of lung cancer. Furthermore, we found that ZEB1 knockdown suppresses the growth of lung cancer cells. In addition, we also showed ZEB1 knockdown suppresses the growth of malignant pleural mesothelioma cells. These results suggest that ZEB1 may be a promising therapeutic target for lung cancer and malignant pleural mesothelioma.

▼display all

To the head of KAKENHI (Grants-in-Aid for Scientific Research).▲
 

Teaching Experience (On-campus) 3

  1. PBLチュートリアル担当

    2023

    　詳細を見る

    2023年5月30日、6月2日、6日WEBにて　＃3胸痛を担当discussionを行った。

  2. Team approach for cancer chemotherapy

    2023

  3. 腫瘍学概論

    2023

    　詳細を見る

    2023年8月1日オンデマンド講義にて令和5年度「がん看護研修Ⅰ」として学内外の看護師を対象として行った。

To the head of Teaching Experience (On-campus).▲

Teaching Experience (Off-campus) 5

  1. 高齢者がん

    2021 （Shimane University）

    　More details

    Level：Undergraduate (specialized) 

  2. 2015.4 - 2016.3 （Aichi Prefectural University）

  3. 2014.4 - 2015.3 （Aichi Prefectural University）

  4. 2013.4 - 2014.3 （Aichi Prefectural University）

  5. 2012.4 - 2013.3 （Aichi Prefectural University）

To the head of Teaching Experience (Off-campus).▲
 

Social Contribution 2

  1. がん教育授業「がんについて深く探究する」

    Role(s)：Lecturer

    愛知県立明和高等学校  スーパーサイエンススクール生物α特別授業　１年普通科全員5回実施  明和高等学校 図書室   2023.12

    　More details

    Audience： High school students,　Teachers

    Type：Visiting lecture

  2. 「がん医療 とがん教育」

    Role(s)：Lecturer

    愛知県学校保健会県立学校部養護教諭会、 愛知県学校保健会県立学校部会　  令和5年度 愛知県学校保健会県立学校部養護教諭会 第2回研究会  名古屋市公会堂  2023.10

    　More details

    Audience： Teachers,　Governmental agency

To the head of Social Contribution.▲